A strategy of vascular‐targeted therapy for liver fibrosis
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Background and Aims: No effective treatments are available for liver fibrosis. Angiogenesis is deeply involved in liver fibrogenesis. However, current controversial results suggest it is difficult to treat liver fibrosis through vascular targeting. There are three different microvessels in liver: portal vessels, liver sinusoids, and central vessels. The changes and roles for each of the three different vessels during liver fibrogenesis are unclear. We propose that they play different roles during liver fibrogenesis, and a single vascular endothelial cell (EC) regulator is not enough to fully regulate these three vessels to treat liver fibrosis. Therefore, a combined regulation of multiple different EC regulatory signaling pathway may provide new strategies for the liver fibrosis therapy. Herein, we present a proof‐of‐concept strategy by combining the regulation of leukocyte cell‐derived chemotaxin 2 (LECT2)/tyrosine kinase with immunoglobulin‐like and epidermal growth factor–like domains 1 signaling with that of vascular endothelial growth factor (VEGF)/recombinant VEGF (rVEGF) signaling. Approach and Results: The CCl 4‐induced mouse liver fibrosis model and NASH model were both used. During fibrogenesis, vascular changes occurred at very early stage, and different liver vessels showed different changes and played different roles: decreased portal vessels, increased sinusoid capillarization and the increased central vessels the increase of portal vessels alleviates liver fibrosis, the increase of central vessels aggravates liver fibrosis, and the increase of sinusoid capillarization aggravates liver fibrosis. The combinational treatment of adeno‐associated viral vector serotype 9 (AAV9)–LECT2–short hairpin RNA (shRNA) and rVEGF showed improved therapeutic effects, but it led to serious side effects. The combination of AAV9‐LECT2‐shRNA and bevacizumab showed both improved therapeutic effects and decreased side effects. Conclusions: Liver vascular changes occurred at very early stage of fibrogenesis. Different vessels play different roles in liver fibrosis. The combinational treatment of AAV9‐LECT2‐shRNA and bevacizumab could significantly improve the therapeutic effects on liver fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Single-cell spatial reconstruction reveals global division of labour in the mammalian liver
Halpern, K. B., Shenhav, R., Matcovitch-Natan, O., Tóth, B., Lemze, D., Golan, M., Massasa, E. E., Baydatch, S., Landen, S., Moor, A. E., et al. (2017) · Nature · doi:10.1038/nature21065 · Cited by 1,059 · cited 1×
“Consistent with these graded microenvironments, liver zonation with different metabolic pathways is formed along the lobular axis.[20,21] The structures of each liver microvessel is different: The portal vessels and central vessels are lined by a continuous endothelial cells (ECs) lying on a basement membrane, and liv…”
BackgroundXie, G., Wang, X., Wang, L., Wang, L., Atkinson, R. D., Kanel, G. C., Gaarde, W. A., & DeLeve, L. D. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.017 · Cited by 410
Angiogenesis in chronic liver disease and its complications: Angiogenesis in CLD
Coulon, S., Heindryckx, F., Geerts, A., Van Steenkiste, C., Colle, I., & Van Vlierberghe, H. (2011) · Liver International · doi:10.1111/j.1478-3231.2010.02369.x · Cited by 276
Broad Distribution of Hepatocyte Proliferation in Liver Homeostasis and Regeneration
Chen, F., Jimenez, R. J., Sharma, K., Luu, H. Y., Hsu, B. Y., Ravindranathan, A., Stohr, B. A., & Willenbring, H. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2019.11.001 · Cited by 236
Su, T., Yang, Y., Lai, S., Jeong, J., Jung, Y., McConnell, M., Utsumi, T., & Iwakiri, Y. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.12.007 · Cited by 220 · cited 2×
“Consistent with these graded microenvironments, liver zonation with different metabolic pathways is formed along the lobular axis.[20,21] The structures of each liver microvessel is different: The portal vessels and central vessels are lined by a continuous endothelial cells (ECs) lying on a basement membrane, and liv…”
BackgroundPlanas-Paz, L., Sun, T., Pikiolek, M., Cochran, N. R., Bergling, S., Orsini, V., Yang, Z., Sigoillot, F., Jetzer, J., Syed, M., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.04.005 · Cited by 216
Matsumoto, T., Wakefield, L., Tarlow, B. D., & Grompe, M. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2019.11.014 · Cited by 194
Purification and primary amino acid sequence of a novel neutrophil chemotactic factor LECT2
Yamagoe, S., Yamakawa, Y., Matsuo, Y., Minowada, J., Mizuno, S., & Suzuki, K. (1996) · Immunology Letters · doi:10.1016/0165-2478(96)02572-2 · Cited by 178 · cited 1×
“[22] Secreting protein LECT2 was initially identified as a chemoattractant of neutrophils, stimulating the growth of chondrocytes and osteoblasts[29,30] and participating in many pathological conditions, such as sepsis,[31] diabetes,[32] systemic amyloidosis,[33,34] liver cancer,[35] NAFLD,[36] and hematopoietic stem…”
BackgroundLECT2 functions as a hepatokine that links obesity to skeletal muscle insulin resistance
Lan, F., Misu, H., Chikamoto, K., Takayama, H., Kikuchi, A., Mohri, K., Takata, N., Hayashi, H., Matsuzawa-Nagata, N., Takeshita, Y., et al. (2014) · Diabetes · doi:10.2337/db13-0728 · Cited by 158
Cited by
Akkız, H., Gieseler, R. K., & Canbay, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147873 · Cited by 191
“Recently, Lin et al. suggested a therapeutic strategy by targeting leukocyte-derived chemotaxis 2/tyrosine kinase with immunoglobulin-like and epidermal growth factor-like domain (LECT2/Tie1) signaling with bevacizumab (anti-VEGF/VEGFR signaling) to reverse fibrosis [199,216,217].”
BackgroundThe evolving role of liver sinusoidal endothelial cells in liver health and disease
McConnell, M. J., Kostallari, E., Ibrahim, S. H., & Iwakiri, Y. (2023) · Hepatology · doi:10.1097/hep.0000000000000207 · Cited by 189
“…(AAV9-LECT2-shRNA) or the combination of AAV9-LECT2-shRNA with bevacizumab (VEGF neutralizing antibody) ameliorated CCl 4 -induced liver fibrosis in mice (94, 95) Portal hypertension is a complication of chronic liver disease which is often characterized by high pressures in the liver sinusoids.”
Angiocrine signaling in sinusoidal homeostasis and liver diseases
Gao, J., Lan, T., Kostallari, E., Guo, Y., Lai, E., Guillot, A., Ding, B., Tacke, F., Tang, C., & Shah, V. H. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.05.014 · Cited by 90
Liu, J., Liu, J., Mu, W., Ma, Q., Zhai, X., Jin, B., Liu, Y., & Zhang, N. (2024) · ACS Nano · doi:10.1021/acsnano.4c02380 · Cited by 74
Xu, H., Wu, Z., Qin, J., Li, X., Xu, F., Wang, W., Zhang, H., Yin, H., Zhu, S., Zhang, W., et al. (2025) · Gut · doi:10.1136/gutjnl-2024-334318 · Cited by 15
“17 Our research showed increased LECT2 levels after hepatocyte stimulation by CCl4, promoting liver fibrogenesis via the Tie1 receptor.”
Self-citation
Metadata
- Authors
- Lin, Y., Dong, M., Liu, Z., Xu, M., Huang, Z., Liu, H., Gao, Y., & Zhou, W.
- Venue
- Hepatology
- Published
- 2022-01-16
- Volume
- 76
- Issue
- 3
- Pages
- 660-675
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W4200560098
- Cited by
- 99
- References
- 10
- FWCI
- 7.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A strategy of vascular‐targeted therapy for liver fibrosis. https://app.cochat.ai/papers/10.1002/hep.32299
- The paper
- Lin, Y., Dong, M., Liu, Z., Xu, M., Huang, Z., Liu, H., Gao, Y., & Zhou, W. (2022). A strategy of vascular‐targeted therapy for liver fibrosis. Hepatology. https://doi.org/10.1002/hep.32299
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.